Madrigal Pharmaceuticals (MDGL) PT Raised to $390 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
TD Cowen analyst Ritu Baral raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $390.00 (from $349.00) while maintaining an Outperform rating.
The analyst commented, "FDA approved THR-β agonist Rezdiffra (resmetirom) for NASH with moderate to advanced fibrosis 'consistent with F2/F3,' with no biopsy requirement in indication language. The label is very clean with no market-limiting warnings, monitoring requirements or contraindications. A $47.4K WAC was announced, with specialty distribution. We model FY24 sales of $97M and peak sales of $4.9B in 2031."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Madrigal shares real-world Rezdiffra data at AASLD 2026
- Snap Inc (SNAP) PT Lowered to $7 at Raymond James
- AMC Entertainment (AMC) PT Raised to $5 at StoneX
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
